Table 6. Review of world real-life experience in use of MKI in DTC.
| Country | Year | Authors | Number of centers | Drugs | Number of subjects | 1st line MKI or more | Median PFS (months) | Prognostic Factors |
|---|---|---|---|---|---|---|---|---|
| United States | 2010 | Cabanillas and cols. | Single center | Sorafenib
Sunitinib |
15 DTC | 1st line or more | 19 | Yes: Log Tg |
| Italy | 2013 | Marotta and cols. | Single center | Sorafenib | 17 | 1st line | 9 | Yes:
Tg levels and Tg response to treatment, baseline FDG-PET |
| France | 2014 | Massicotte and cols. | Multicenter | Sorafenib
Sunitinib Vandetanib |
45 DTC
(17 MTC) |
1st line or more | 7.0 (1st line DTC) | No |
| Turkey | 2015 | Benekli and cols. | Unclear (Turkish Ministry of Health database) | Sorafenib | 14 DTC
(16 MTC) |
Unclear | 21.3 (DTC group) | No |
| France | 2017 | Berdelou and cols. | Multicenter | Lenvatinib | 75 | 1st line or more | 10 | No |
| Spain | 2018 | Molina-Vega and cols. | Single center | Sorafenib
Lenvatinib Axitinib |
17 | 1st line or more | 18 | No |
| Korea | 2018 | Mijin Kim and cols. | Multicenter | Sorafenib | 98 | 1st line | 9.7 | Yes:
Symptoms, lung-only metastasis, daily maintenance dose, Tg reduction |
| Switzerland* | 2018 | Balmelli and cols. | Multicenter | Lenvatinib | 13 | 1st line or more | 7.2 | Yes: Tg levels (with radiologic response) |
| Japan | 2018 | Sugino | Single center | Lenvatinib | 29 | 1st line or more | 24.3 | Symptom |
| Korea | 2019 | Kim and cols. | Multicenter | Sorafenib | 85 | 1st line or more | 14.4 | Yes:
Small tumor size, long doubling time |
| Japan | 2019 | Suzuki and cols. | Single center | Lenvatinib | 26 | 1st line or more | 2 year-PFS= 58.4% | Yes:
Baseline tumor size and symptoms |
| Japan | 2019 | Yamazaki and cols. | Single center | Lenvatinib | 36 | 1st line or more | Full Dose: 696 days
Low Dose: not reached |
No |
| Korea | 2019 | Lee and cols. | Multicenter (11) | Lenvatinib | 67 | 1st line or more | 5.1 | Yes:
Rapidly PD with shorter initial tumor doubling time |
| Italy | 2019 | Locati and cols. | Multicenter (16) | Lenvatinib | 94 | 1st line or more | 10.8 | No |
| Argentina | 2019 | Jerkovich and cols. | Single center | Sorafenib
Lenvatinib |
22 | 1st line or more | 31.5
(16.5 −1st line only) |
No |
| Japan | 2019 | Iwasaki and cols. | Multicenter | Sorafenib
Lenvatinib |
56 | 1st line | Median treatment duration:
Sorafenib 5.1 Lenvatinib 14.1 |
Yes:
Pulmonary metastasis as target lesion |
| Portugal | 2019 | Santos and cols. | Single center | Sorafenib
Sunitinib |
28 | 1st line or more | 10.8 (1st line sorafenib) | No |
| China | 2020 | Cheng and cols. | Single center | Sorafenib | 72 | 1st line | 17.6 | Yes:
Hand-foot syndrome, Well DTC, ECOG PS ≤ 2, biochemically nonineffective response, lung-only metastasis, and absence of bone metastasis |
| Argentina | 2020 | Jerkovich and cols. | Multicenter (02) | Lenvatinib | 22 | 1st line or more | 13.7 | No |
| Netherlands | 2020 | Aydermirli and cols. | Multicenter (03) | Lenvatinib | 39 | 1st line or more | 9.7 | No |
| Japan | 2020 | Masaki and cols. | Single center | Lenvatinib | 42 | 1st line or more | 13.8 | No |
| Brazil | 2020 | Treistman and cols. | Single center | Sorafenib | 44 | 1st line | 24 | FDG uptake on target lesions on PET-CT, higher SUV presence of lung-only metastasis and lower Tg during treatment |
TTg: thyroglobulin; DTC: differentiated thyroid cancer; MTC: medullary thyroid cancer; PFS: progression free survival; OS: overall survival; RAI: radioiodine.